Xolair for inner-city kids with asthma (ICATA Trial, NEJM)) - PulmCCM
Advertisement
Mar 152011
 

Busse et al randomized 419 inner-city kids (age 6-20) with uncontrolled, skin-test-positive, mostly severe allergic asthma and IgE < 1,300 IU/mL to 60 weeks of omalizumab or placebo. The treated group had modest improvements: ~1 fewer day of symptoms per month and a 5% absolute reduction in hospitalizations (1.5% vs 6.3%); 18% fewer of them had exacerbations (30% vs 48%), especially during fall & spring. Novartis, other pharmas and the NIH provided funding; most of the investigators reported receiving payments from Novartis. (n=419). NEJM 2011;364:1005-1015.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society or journal referenced on the website.

Leave a Comment